HUTCHMED (China) Ltd (HCM)
About HUTCHMED (China) Ltd
HUTCHMED (China) Ltd is a biopharmaceutical company engaged in the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies world-wide and an extensive commercial infrastructure in its home market, China. The company operates in two reportable segments: Oncology/Immunology and Other Ventures.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $548.5M
- Net income
- $456.9M
- Total assets
- $1.8B
- Market cap
- $1.9B
Source: SEC EDGAR · updated Jun 8, 2026
15-minute delayed · data by Polygon.io
Past year · hover for prices
52-week range
- Market cap
- $1.9B
- Shares outstanding
- 169.8M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Mar 17, 2016
HUTCHMED (China) Ltd (HCM) Stock Price
- Profitable — net income of $456.9M in FY2025.
- Trading 43% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review HUTCHMED (China) Ltd.
Write a review
News about HUTCHMED (China) Ltd
News & sentiment via Polygon.io
HUTCHMED (China) Ltd: frequently asked questions
Is HUTCHMED (China) Ltd an American company?
HUTCHMED (China) Ltd is a US-based company, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.
Is HUTCHMED (China) Ltd publicly traded?
Yes — HUTCHMED (China) Ltd is a publicly traded company. Its stock trades under the ticker symbol HCM on the NASDAQ.
What does HUTCHMED (China) Ltd do?
HUTCHMED (China) Ltd is an American Pharmaceuticals company in the Health & Beauty sector.
